Infographics
Click any card to open the full infographic.
Ivermectin A Nobel-Winning Medicine the US Buried — What the World's Data Actually Shows
Ivermectin is three stories in one word. As an antiparasitic it is a Nobel Prize-winning (2015), WHO-essential medicine given billions of times — river blindness (50M+ treated yearly), strongyloidiasis, scabies (an 88% drop in a 26,188-person program) — and it is safer than the Tylenol in your cabinet. As a COVID medicine it was used by whole countries with strong real-world results (Brazil's 223,128-person Itajaí program: up to 92% lower death in regular users, dose-response; India's Uttar Pradesh/Delhi/Goa rollouts; Peru; the Bryant 24-RCT meta showing reduced mortality) — while the United States ridiculed it ('you are not a horse'), pharmacies refused legal prescriptions, doctors were deplatformed and decertified, and the one question that mattered was never funded to a fair answer, because a $25 generic cannot compete for research dollars with a $1,400 patented pill. The establishment 'negative' trials (TOGETHER, ACTIV-6) used a single low dose given late and are shown here as one interested position, not the verdict. As a cancer therapy it is an emerging, genuinely promising frontier — real activity against breast/ovarian/colorectal models via Wnt and the P-glycoprotein pump — starved of the human trials nobody will fund. Follow the money: the party that profits from 'it doesn't work' is the industry that loses billions if it does. You decide.
VERVE-102 The One-Time Gene Edit Aiming to Lower Cholesterol for Life
VERVE-102 is Eli Lilly's experimental one-time gene-editing infusion that claims to permanently switch off the PCSK9 gene to lower cholesterol for life. The genetics behind the idea are rock-solid, but the product itself is investigational (not approved), tested in only ~35 people, irreversible, industry-reported, and precedent puts one-time gene therapies at $2-3M — so read the striking early numbers as a sponsor's press release, not settled science.
NAD+ (NMN / NR) What the Research Actually Shows
NAD+ precursors (NMN, NR) reliably raise blood NAD+ in international human trials — and the FDA moved to ban NMN from the supplement market in 2022, right after a company co-founded by NMN's own lead researcher filed to patent it as a drug. Follow the money, see what Japan and China never stopped selling, and decide for yourself.
Berberine Cholesterol, Arterial Plaque & Blood Sugar — What the Research Actually Shows
Berberine is a 1,400-year-old Chinese and Ayurvedic medicine with a deep, mostly Chinese-run randomized-trial base showing real cholesterol and blood-sugar effects — sold as a US 'supplement' not because the science is weak, but because a plant compound can't be patented, so no drug company will fund the mega-trial that would compete against its own $100B+ statin/metformin/GLP-1 franchise.
Beta-Glucan What the Research Actually Shows
Beta-glucan is really three fibers under one name: the oat/barley type genuinely lowers cholesterol, the yeast type is sold hard by one company with thin proof (EFSA rejected its immune claim), and — largely unknown in the US — Japan has prescribed mushroom-derived beta-glucan alongside chemotherapy for 40 years, with real but mixed survival data. Cheap and very safe across all three; the honest split is strength of evidence and who's funding the claim, not hype vs no-hype.
Ubiquinol vs CoQ10 What the Research Actually Shows
CoQ10 vs its pricier cousin ubiquinol — the head-to-head absorption data is more mixed than the marketing (the best elderly trial found no significant edge), the landmark heart-failure trial and its independent Russian and Japanese confirmations used the cheaper ubiquinone form, and statins quietly deplete your CoQ10 in a way nobody's commercially incentivized to tell you. Cheap and safe either way.
GHK-Cu (Copper Peptide) What the Research Actually Shows
GHK-Cu is a naturally-occurring copper peptide with genuine (if industry-funded) human evidence for topical anti-aging and deep animal/lab evidence for wound healing. The injectable form remains unreviewed by regulators — not because it was tested and found wanting, but because an unpatentable 50-year-old molecule has no company willing to fund the trial; the largest human injectable dataset came from India, not the US.
Aromatase Inhibitors What They're Actually Used For
Three cheap generic estrogen-blockers — rock-solid FDA-approved for postmenopausal breast cancer and the world's first-line PCOS fertility drug (letrozole). Off-label in men's TRT and male infertility the FDA and Endocrine Society have taken no position at all; real-world data shows judicious use working and crashed-estradiol harm when it isn't, so we show both and hand you the decision.
TB-500 (Thymosin β-4) What the Research Actually Shows
TB-500's real science is filed under thymosin beta-4 — a natural repair peptide with genuine, internationally-run human trials for dry eye and skin ulcers (Italy, Poland, Korea-funded). The muscle/tendon/joint use it's sold for has strong animal evidence but no human trials anywhere yet, because it's an unpatentable fragment nobody has funded to test — not because it's been disproven. WADA-banned for athletes.
NAC (N-Acetylcysteine) What the Research Actually Shows
A 60-year-old WHO-essential medicine — the ER antidote for Tylenol overdose — that the FDA moved to ban as a supplement in 2020 on a legal technicality, while Europe sold it over the counter the whole time. Cheap, safer than the drug it treats, with real early GlyNAC/anti-aging promise and a genuinely mixed COVID record reported straight. (No pharma villain invented where the evidence didn't show one.)
Glycine What the Research Actually Shows
Glycine is a cheap, genuinely safe amino acid with real (if modest) sleep evidence — backed by Japan's own government sleep-health claim — plus a promising, internationally-replicating GlyNAC anti-aging story. No company profits from it, which is exactly why the trials stay small, not because anyone's hiding something. Near-zero risk to try.
DMSO What It's Actually Used For
DMSO has two FDA approvals (human bladder, animal trauma) and a 55-year run as a registered prescription anti-inflammatory in Russia — the same 'sore joint' use Americans still do off-label — because the US trials were halted in 1965 over an unrelated animal-safety scare and never resumed for a drug nobody can patent. A decades-long low-toxicity record and real international clinical use make it worth an honest look, not a dismissal.
Iron What the Research Actually Shows
Iron deficiency is real and common — but so is iron overload, which your body cannot reverse on its own. This page centers YOUR ferritin number over any institution's agenda, with international data (Denmark's fortification reversal, the Zanzibar trial stopped early for excess deaths) showing what happens when 'just take more iron' gets tested in the real world.
Hyaluronic Acid What the Research Actually Shows
What the research actually shows about hyaluronic acid — organized by how people really take it (joints, skin, eyes), with oral use front and center — including the Japanese science that pioneered oral HA, honest international guideline data on the injections (20 of 27 countries recommend them), and the real money question behind the injection debate most pages skip. Very safe: little reason not to try the cheap oral form.
L-Theanine What the Research Actually Shows
L-theanine's real research base is mostly Japanese, not American — decades of Tokyo and Nagoya trials on stress, sleep, and even schizophrenia and ADHD that never make US supplement blogs. Genuinely one of the safest compounds we've covered: no found overdose ceiling, non-habit-forming, and a real (if honestly debated) case for benefit.
Betaine (TMG) What the Research Actually Shows
Betaine (TMG) has one real, modest strength benefit and reliably lowers homocysteine — but it's a cheap, unpatentable molecule nobody funds large human trials on, so the evidence stays thinner than its safety record deserves. The 'raises LDL' warning is real but narrower than advertised: it shows up only at higher doses in people who already have metabolic risk.
Niacin (Vitamin B3) What the Research Actually Shows
Niacin: an essential B vitamin most people already get from food — and at ~100x that dose, a cheap generic heart drug with a real outcome-trial record (it beat patented ezetimibe head-to-head on artery thickness) that lost ground the same years two $14,000/year patented alternatives launched. High-dose liver toxicity and a 2024 inflammation signal are real; this dose belongs under a doctor's care.
Taurine What the Research Actually Shows
Taurine is a cheap, unpatentable amino acid with real cardiometabolic evidence and a 40-year approved heart-failure-drug history in Japan the US press rarely mentions. The 2023 longevity finding wasn't debunked in 2025 — just narrowed — and the human trial that would settle it has never been funded, because no one profits from it. Genuinely safe: the downside of trying it is close to zero.
Creatine Monohydrate What the Research Actually Shows
Creatine is the most-proven supplement on the shelf — hundreds of trials back real strength and muscle gains, and the kidney / hair-loss / 'steroid' scares are myths that don't survive contact with the data. The honest other half: recent hype calling it a brain-disease cure or belly-fat melter has outrun the trials, which came back negative. This page busts the myths in both directions.
THC What the Research Actually Shows
THC was isolated in Israel in 1964 and is regulated as medicine or public-health policy in Israel, Canada, Germany, the Netherlands, and Portugal — while the US kept it Schedule I for 50+ years under a government research monopoly and documented pharma lobbying. This page weighs the world's data, the real risks, and who profits from which answer, without handing the reader Washington's verdict as the final word.
Antidepressants What the Research Actually Shows
Antidepressants: real benefit for some, oversold by decades of marketing. Covers the FDA's own unpublished trial data (Kirsch), a documented ghostwritten fraud (Study 329), why withdrawal was undersold for 20 years, France's therapy-first default, and why a $17B+ ad industry has every reason to tell you the good news louder than the bad.
GLP-1 Bait & Switch How the Affordable Version Got Shut Down
Millions of Americans legally got compounded Ozempic/Wegovy/Mounjaro/Zepbound for ~$200/month during the shortage — until the two patent holders, who made $69.5 billion combined in 2025 on these drugs, got it banned, sued the compounders, and are now facing a federal antitrust suit accusing them of coordinating to kill that competition. See what the rest of the world pays, and judge the timing for yourself.
Retatrutide The Triple-Agonist Phase 3 Just Confirmed
Eli Lilly's investigational triple-hormone-receptor drug posted a striking 28.3% weight-loss claim in its own 2026 press release — but that number hasn't cleared independent peer review, published trial data shows a meaningful share of the weight lost is muscle, and the FDA hasn't approved it. A genuinely strong candidate wrapped in real unknowns: long-term safety, cost, and access all remain open. Follow the money — the trials are Lilly-run and a $13B franchise is at stake.
BPC-157 What the Research Actually Shows
A stomach-derived healing peptide studied continuously since 1993 by a Croatian lab, with an unusually clean animal safety record (LD1 never reached) and real if small human pilot data — thin on large trials mainly because an unpatentable peptide has no sponsor to fund a Phase III. The US reversed its 2023 compounding ban in early 2026; the world's evidence, not just Washington's, is the honest picture. (Originator's commercial conflicts disclosed.)
Request a Topic
Got a health topic, compound, supplement, or peptide you want covered with the same evidence-honest treatment? Tap the button — it opens a short email with three boxes to fill in. The most important is the first one: name the topic (one compound or subject). We'll research it and add it to the library.
Request an Infographic Topic →Tip: put the topic on the first line. The other two boxes are optional.